GLP-1 RA treatment has been shown to reduce pro-inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1β, and IL-6, and thereby increase anti-inflammatory adiponectin in patients with T2DM [41]. This evidence concerns the gene TNF and type 2 diabetes mellitus.